LIfT’s Technology –

Allogeneic Innate Cell Therapy

N-LIfT is classified as an allogeneic ATMP, in which neutrophils derived from stem cells, originating from a single donor can provide treatments to a large number of patients. Allogeneic therapies are “off the shelf”, a more practical solution that can be administered to any patient upon diagnosis, rather than having to wait precious weeks to harvest and manufacture cells for each individual patient. LIfT is attempting to overcome limitations, such as those experienced in autologous therapies.


Donor screening and testing is needed to establish donor’s infectious status, genetic predisposition to pertinent diseases and susceptibility to cancer. Furthermore, only donors who demonstrate having neutrophils with N1a characteristics are invited back for G-CSF mobilised leukapheresis. These leukapheresis products are haematopoietic stem cell (HSC) rich that gives a better starting cell number for HSC selection and expansion. N1a neutrophils are derived from these donor stem cells in large-scale using LIfT’s proprietary manufacturing platform. The product N-LIfT is harvested, cryopreserved and stored in LIfT Biosciences cell bank to be shipped to patients in designated hospitals.

Disclaimer: The information, documents and graphic depictions (the "Information") published on this Web site are the property of LIfT BioSciences Ltd. LIfT BioSciences assumes no responsibility for errors or omissions in the Information on this website. In no event shall LIfT BioSciences be liable for any special, direct, indirect, consequential, or incidental damages or any damages whatsoever, whether in an action of contract, negligence or other tort, arising out of or in connection with the use of this Web site or the Information. LIfT BioSciences reserves the right to make additions, deletions, or modification to the Information on the Web site at any time without prior notice.

  • CEO's Linked-in
  • CEO's Twitter
  • LIfTBio on Facebook

©2016 LIfT BioSciences Ltd